<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078452</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00075658</org_study_id>
    <secondary_id>NCI-2017-00308</secondary_id>
    <secondary_id>Winship2656-14</secondary_id>
    <nct_id>NCT03078452</nct_id>
  </id_info>
  <brief_title>Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy</brief_title>
  <official_title>Comparison of Quality of Bone Marrow Biopsy and Patient Convenience and Pain Control by a Battery Powered Drill Versus Conventional Methods in Patients With Plasma Cell Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the introduction of the Jamshidi needle in 1971, new advances in bone marrow sampling&#xD;
      have not been seen. In 2007, a new battery-powered bone marrow biopsy system was developed.&#xD;
      This technology, using a battery-powered drill to operate the needle accessing the posterior&#xD;
      iliac bone, was approved by the Food and Drug Administration (FDA) and is currently&#xD;
      commercially available.&#xD;
&#xD;
      Few randomized controlled trials (RCTs) have compared the use of the battery-powered bone&#xD;
      marrow biopsy system to the Jamshidi needle (the traditional manual) method of bone marrow&#xD;
      sampling. This research study is designed to evaluate the effectiveness of the Jamshidi&#xD;
      needle compared to the battery-powered bone marrow biopsy system.&#xD;
&#xD;
      100 participants will be enrolled in this study at Emory University.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Assessing the quality and quantity of bone marrow core biopsies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assessing the nature of pain by established visual analogue scale (VAS) questionnaires.&#xD;
&#xD;
      II. Timing of the actual procedure.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo bone marrow biopsy using the power drill.&#xD;
&#xD;
      ARM II: Patients undergo bone marrow biopsy using the traditional Jamshidi needle.&#xD;
&#xD;
      All patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3,&#xD;
      and 7.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone marrow core biopsy length (in mm) and artifacts assessed by the pathologist</measure>
    <time_frame>At the time of biopsy</time_frame>
    <description>Bone marrow biopsy length is studied with mean, median, range, and standard deviation and compared by two-sample t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain measured using visual analogue scale (VAS) pain questionnaire</measure>
    <time_frame>At the time of, 30 minutes, 1, 3, and 7 days after biopsy</time_frame>
    <description>The VAS (visual analogue scale) for pain is on a 10 point scale. Pain is studied with chi-square, Mann Whitney U test, or Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken by the procedure measured in seconds using a stopwatch</measure>
    <time_frame>At the time of biopsy</time_frame>
    <description>Staff members will use a stopwatch from the beginning to the completion of the procedure (skin to skin). Time taken for procedure is studied with mean, median, range, and standard deviation and compared by two-sample t-test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm I (biopsy using power drill)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (biopsy using Jamshidi needle)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Power drill</intervention_name>
    <description>Undergo bone marrow biopsy using power drill</description>
    <arm_group_label>Arm I (biopsy using power drill)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Jamshidi needle</intervention_name>
    <description>Undergo bone marrow biopsy using Jamshidi needle</description>
    <arm_group_label>Arm II (biopsy using Jamshidi needle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with existing plasma cell disorders and no history of psychiatric&#xD;
             disorders who can receive conscious sedation are eligible to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women are excluded from participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Nooka, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajay Nooka, MD, MPH</last_name>
    <phone>404-778-4191</phone>
    <email>anooka@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Shipp</last_name>
      <phone>404-778-4191</phone>
      <email>jennifer.shipp@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eduardo Sanabria</last_name>
      <phone>404-778-2164</phone>
      <email>esanab2@emory.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Ajay Nooka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

